Head and Neck Cancer Clinical Trial
Official title:
Phase II Trial Of Combretastatin A-4 Phosphate (CA4P) In Advanced Anaplastic Carcinoma Of The Thyroid
RATIONALE: Combretastatin A4 phosphate may stop the growth of anaplastic thyroid cancer by
stopping blood flow to the tumor.
PURPOSE: This phase II trial is studying how well combretastatin A4 phosphate works in
treating patients with advanced recurrent or metastatic anaplastic thyroid cancer.
Status | Completed |
Enrollment | 26 |
Est. completion date | January 2008 |
Est. primary completion date | February 2007 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
DISEASE CHARACTERISTICS: - Histologically confirmed* anaplastic or poorly differentiated variant thyroid cancer, including 1 of the following: - Recurrent/regionally advanced disease no longer amenable to definitive curative surgery or radiotherapy - Untreated metastatic disease NOTE: *If original/diagnostic tumor blocks are unavailable, tumor must be accessible for pretreatment core needle biopsy - Must have relapsed or progressed during or after prior combined modality therapy (e.g., systemic chemotherapy and radiotherapy) for regionally advanced (but not metastatic) disease - Measurable or evaluable disease - Patent trachea and airway by screening direct and indirect laryngoscopy* NOTE: *For patients with bulky thyroid/neck masses and/or suspected airway obstruction - No active brain metastases, as evidenced by any of the following: - Symptomatic involvement - Cerebral edema by CT scan or MRI - Radiographic evidence of progression since definitive therapy - Continued requirement for corticosteroids PATIENT CHARACTERISTICS: Age - 18 and over Performance status - ECOG 0-2 Life expectancy - At least 12 weeks Hematopoietic - Absolute granulocyte count at least 1,500/mm^3 - Platelet count at least 75,000/mm^3 - Hemoglobin at least 8.5 g/dL Hepatic - Bilirubin no greater than 1.5 times upper limit of normal (ULN) - ALT and AST no greater than 3.5 times ULN Renal - Creatinine no greater than 1.5 times ULN Cardiovascular - LVEF at least 50% by MUGA - EKG normal - No evidence of prior myocardial infarction (e.g., significant Q waves), QTc greater than 450 msec, or other clinically significant abnormalities - No history of angina (even if controlled by medication) - No congestive heart failure - No uncontrolled atrial arrhythmias - No clinically significant arrhythmias, including any of the following: - Conduction abnormalities - Nodal junctional arrhythmias and dysrhythmias - Sinus bradycardia or tachycardia - Supraventricular arrhythmias - Atrial fibrillation or flutter - Syncope or vasovagal episodes - No significant heart wall abnormality or heart muscle damage by MUGA - No uncontrolled hypertension (blood pressure consistently greater than 150 mm Hg systolic and 100 mm Hg diastolic regardless of medication) - Patients with previous hypertension are allowed provided there is clinical documentation of controlled blood pressure for 2 months prior to study enrollment - No symptomatic peripheral vascular disease - No symptomatic cerebrovascular disease Other - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception - No grade 2 or greater preexisting motor or sensory peripheral neuropathy - No uncontrolled hypokalemia or hypomagnesemia - No concurrent serious infection - No other nonmalignant medical illness that is uncontrolled or whose control may be jeopardized by study therapy - No psychiatric disorders or other conditions that would preclude study compliance PRIOR CONCURRENT THERAPY: Biologic therapy - No concurrent biologic therapy - No concurrent immunotherapy - No concurrent prophylactic colony-stimulating factors (e.g., filgrastim [G-CSF] or sargramostim [GM-CSF]) Chemotherapy - See Disease Characteristics - At least 3 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) - No other concurrent chemotherapy Endocrine therapy - See Disease Characteristics - No concurrent hormonal therapy, except any of the following: - Gonadotropin-releasing hormone agonists for hormone-refractory prostate cancer - Hormone replacement therapy - Oral contraceptives - Megestrol for anorexia/cachexia Radiotherapy - See Disease Characteristics - More than 4 weeks since prior radiotherapy with progressive disease beyond radiation ports - No prior radiotherapy to more than 30% of the bone marrow - No concurrent radiotherapy Surgery - See Disease Characteristics - More than 4 weeks since prior major surgery Other - At least 6 weeks since other prior therapy associated with delayed toxicity - No prior therapy for metastatic disease - No concurrent medication(s) known to prolong the QTc interval, unless medication(s) can be held for at least 72 hours before, during, and for at least 6 hours after study drug administration - No other concurrent investigational therapy - No other concurrent antineoplastic or cytotoxic therapy |
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Ireland Cancer Center at University Hosptials Case Medical Center, Case Comprehensive Cancer Center | Cleveland | Ohio |
United States | Josephine Ford Cancer Center at Henry Ford Hospital | Detroit | Michigan |
United States | Hillman Cancer Center at University of Pittsburgh Cancer Institute | Pittsburgh | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
Case Comprehensive Cancer Center | National Cancer Institute (NCI) |
United States,
Mooney CJ, Nagaiah G, Fu P, Wasman JK, Cooney MM, Savvides PS, Bokar JA, Dowlati A, Wang D, Agarwala SS, Flick SM, Hartman PH, Ortiz JD, Lavertu PN, Remick SC. A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of b — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Median survival | every 8 weeks | No | |
Secondary | Objective disease response | every 8 weeks | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05808920 -
The RESCUE Study: Survival and Functional Outcomes Following Salvage Surgery for RESidual or reCurrent sqUamous cEll Carcinoma of the Head and Neck
|
||
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT03997643 -
Preservation of Swallowing in Respected Oral Cavity Squamous Cell Carcinoma: Examining Radiation Volume Effects (PRESERVE): A Randomized Trial
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04700475 -
Effect of Low Level Laser Therapy on Prevention of Radiotherapy Induced Xerostomia in Cancer Patients.
|
N/A | |
Withdrawn |
NCT04058145 -
AMD3100 Plus Pembrolizumab in Immune Checkpoint Blockade Refractory Head and Neck Squamous Cell Carcinoma
|
Phase 2 | |
Completed |
NCT02572869 -
Functional and Aesthetic Outcomes After Mandible Reconstruction With Fibula Osteomyocutaneous Free Flaps
|
||
Active, not recruiting |
NCT04474470 -
A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer
|
Phase 1/Phase 2 | |
Withdrawn |
NCT05073809 -
Photoacoustic Imaging of Head and Neck Tumours
|
||
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Active, not recruiting |
NCT03651570 -
Randomized Controlled Trial of a E-intervention to Help Patients Newly Diagnosed With Cancer Cope Better: Pilot Study
|
N/A | |
Recruiting |
NCT04930432 -
Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06016699 -
Immunological Function After Radiation With Either Proton or Photon Therapy
|
||
Terminated |
NCT03843554 -
Commensal Oral Microbiota in Head and Neck Cancer
|
N/A | |
Recruiting |
NCT05915572 -
Mulligan Technique on Shoulder Dysfunction
|
N/A | |
Completed |
NCT05897983 -
Tens and Rocabado Exercises on TMJ Dysfunction
|
N/A | |
Not yet recruiting |
NCT06289049 -
Heavy Strength Training in Head and Neck Cancer Survivors
|
Phase 2 | |
Withdrawn |
NCT05263648 -
Virtual Reality Software to Reduce Stress in Cancer Patients
|
N/A | |
Withdrawn |
NCT03238638 -
A Study of Epacadostat + Pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1/PD-L1 Therapy
|
Phase 2 |